David Jones Companys Strategies for Downsizing

Dark Life essays

Dark Life essays When he lifted his head a little, he saw his vaulted brown belly... were waving helplessly before his eyes. Gregor Samsa has gone through a metamorphosis. This change has turned Gregor into a monstrous vermin. Kafka expresses the anxieties, inner terrors, and cynicism, which fill Gregors life, throughout the story, metamorphosis. Franz Kafka uses these feelings as an element of expressionism to convey Gregors attitudes towards his life and society. Examples depicting this element of expressionism used in the story are Gregors feelings towards his job, the effect his job has on his family, and the cruelty that his family displays. The story opens with Gregor in his monstrous state, late for work. He infers that his job as a traveling salesman is very consequential, yet he is growing tired and frustrated, The upset of doing business is much worse than the actual business in the home office, and, besides, Ive got the torture of traveling, worrying about changing trains, eating miserable food at all hours, constantly seeing new faces, no relationships that last or get more intimate. To the devil with it all! (Scott 221-223) Gregor has a great amount of fury towards his job, which eventually led to his anger towards society as a whole. The fact that his office manager showed up at Gregors house plays an immense role in creating trepidation and anxieties in Gregors mind. Gregor feels strangled by his job and is too weak to tolerate the pressure. In addition to the pressure created by his office manager and society, the Samsas, especially Gregors father, take advantage of him. Gregor earns the basic income to support his family. But of course he actually could have paid off more of his fathers debt to the boss with this extra money, and the clay on which he could have gotten rid of his job would have been much closer, but now things were undou ...

Biosimilar Research Paper Example | Topics and Well Written Essays - 1500 words

Biosimilar - Research Paper Example Although it is the hope that their introduction may lower the cost of such expensive medicinal products, there have been concerns over the introduction and manufacturing considerations, immunogenicity, degree of similarity of these complex drugs, and regulatory approaches to biosimilars around the world. In addition, of concern are arguments and techniques employed by pharmaceutical companies to advance or discredit biosimilars, as well as issues with post-marketing surveillance programs and their limitations. The issues associated with introduction of biosimilar medicines across a range of pharmacological indications are controversial, as well as differences between biopharmaceutical products not subjected to regulatory approval and regulatory approved medicines. There are rapid changes in licensing of biosimilars and regulatory approval. Non-transparent promotion of biosimilar products gives clinicians a need to be wary. Hopefully, widespread availability of biopharmaceutical produ cts will be provided by biosimilar medicines (Roger, 2010). ... The manufacture of a biopharmaceutical involves several isolation and purification steps, and the product is complex. In terms of safety and efficacy of the product, even minor changes in production can have serious implications, and these procedures are proprietary to the manufacturer of the originator product. Existing and future regulation should prevent inappropriate and automatic substitution of a biosimilar for a reference biopharmaceutical product, and biosimilars should not be brought to market using the same procedure applied to generics (Misra A, 2010). Living systems or organisms are used to produce biological products, medicines, and therapeutic agents. Because of their expensive cost, access to these life-saving biological products is limited. In the next few years, patents on the early biological products will soon expire. This will allow other biotech/biopharmaceutical companies to manufacture the generic versions of the biological products, which are referred to as bi osimilar medicinal products by the European Medicine Agency of the European Union, or as follow-on biological products by the U.S. Food and Drug Administration. Increase in patients' access to the much-needed biological pharmaceuticals by competition of cost-effective follow-on biological products with equivalent efficacy and safety can cut down the costs. Evaluation of equivalence (similarity) between the biosimilar products and their corresponding innovator product is a great challenge for both the scientific community and regulatory agencies due to the complexity and heterogeneity of the molecular structure, complicated manufacturing process, different analytical methods, and possibility of severe